Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | PPARD | Q03181 | 1/20 | 0.50 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.50 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.43 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28403037 | 1.00 | GPR84 (0.52) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL2198680 | 1.00 | GPR84 (0.52) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL31084652 | 1.00 | GPR84 (0.52) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL9645892 | 1.00 | GPR84 (0.52) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL2471964 | 1.00 | GPR84 (0.52) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL11690518 | 1.00 | GPR84 (0.52) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL2196952 | 1.00 | GPR84 (0.52) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL11689463 | 1.00 | GPR84 (0.52) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL11768537 | 1.00 | GPR84 (0.52) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL30633658 | 1.00 | GPR84 (0.52) | GPR84FFAR1MAPTLCKPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102099326-A | A 9, 10, 12-triacyloxy octadecanoic acid alkyl ester and 9,10,12-triacyloxy octadecanoic acid alkyl ester rich fatty acid alkyl esters mixture and a process for preparation thereof | COUNCIL SCIENT IND RES | 2011-06-15 | — | — | CN | claimed |
| CN-101679884-A | Triester-based lubricants and methods of making same | CHEVRON USA INC | 2010-03-24 | — | — | CN | claimed |
| US-20230128252-A1 | PHARMACEUTICAL COMPOSITIONS | Shenzhen Pharmacin Co., Ltd. (CN) | 2023-04-27 | — | — | US | disclosed |
| EP-4135699-A1 | PHARMACEUTICAL COMPOSITIONS | Shenzhen Pharmacin Co., Ltd. (CN) | 2023-02-22 | — | — | EP | disclosed |
| CN-115135323-A | Pharmaceutical composition | 深圳市药欣生物科技有限公司 | 2022-09-30 | — | — | CN | disclosed |
| US-20220193095-A9 | PHARMACEUTICAL COMPOSITIONS | Shenzhen Pharmacin Co., Ltd. (CN) | 2022-06-23 | — | — | US | disclosed |
| EP-3914234-A1 | PHARMACEUTICAL COMPOSITIONS | Shenzhen Pharmacin Co., Ltd. (CN) | 2021-12-01 | — | — | EP | disclosed |
| WO-2021209025-A1 | PHARMACEUTICAL COMPOSITIONS | SHENZHEN PHARMACIN CO., LTD (CN) | 2021-10-21 | — | — | WO | disclosed |
| CN-113473974-A | Pharmaceutical composition | 深圳市药欣生物科技有限公司 | 2021-10-01 | — | — | CN | disclosed |
| US-20200237784-A1 | PHARMACEUTICAL COMPOSITIONS | SHENZHEN PHARMACIN CO LTD (CN) | 2020-07-30 | — | — | US | disclosed |
| WO-2020151633-A1 | PHARMACEUTICAL COMPOSITIONS | Shenzhen Pharmacin Co., Ltd. (CN) | 2020-07-30 | — | — | WO | disclosed |
| EP-2344165-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING BORONIC ACID COMPOUNDS | Dr. Reddy's Laboratories, Ltd. (IN) | 2011-07-20 | — | — | EP | disclosed |
| CN-1774414-B | New non-ionic surfactants for solubilizing poorly soluble molecules | ASTRAZENECA AB SE | 2010-12-08 | — | — | CN | disclosed |
| WO-2010039762-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING BORONIC ACID COMPOUNDS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-04-08 | — | — | WO | disclosed |
| EP-1879456-A2 | PHARMACEUTICAL COMPOSITIONS WITH SYNCHRONIZED SOLUBILIZER RELEASE | Lipocine, Inc. (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006119498-A2 | PHARMACEUTICAL COMPOSITIONS WITH SYNCHRONIZED SOLUBILIZER RELEASE | LIPOCINE, INC. (US) | 2006-11-09 | — | — | WO | disclosed |
| EP-1694294-A1 | PHARMACEUTICAL COMPOSITIONS WITH SYNCHRONIZED SOLUBILIZER RELEASE | Lipocine, Inc. (US) | 2006-08-30 | — | — | EP | disclosed |
| CN-1774414-A | New non-ionic surfactants for solubilizing poorly soluble molecules | ASTRAZENECA AB (SE) | 2006-05-17 | — | — | CN | disclosed |
| US-20060003002-A1 | Pharmaceutical compositions with synchronized solubilizer release | LIPOCINE, INC. | 2006-01-05 | — | — | US | disclosed |
| WO-2005041929-A1 | PHARMACEUTICAL COMPOSITIONS WITH SYNCHRONIZED SOLUBILIZER RELEASE | LIPOCINE, INC (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193095-A9 | PHARMACEUTICAL COMPOSITIONS | LIPA, LIPC, MGLL | GPR84 2294/4885FFAR1 245/4885MAPT 2086/4885 |
| US-20230128252-A1 | PHARMACEUTICAL COMPOSITIONS | SLCO4C1, SLCO1B1, SLCO1A2 | GPR84 3431/4885FFAR1 1517/4885MAPT 798/4885 |
| US-20200237784-A1 | PHARMACEUTICAL COMPOSITIONS | LIPA, LIPC, MGLL | GPR84 2294/4885FFAR1 245/4885MAPT 2086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.